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Abstract
Background: Among adipokines and hepatokines, adiponectin and fetuin-A were consistently found to predict the
incidence of type 2 diabetes, both by regulating insulin sensitivity.
Objective: To determine to what extent circulating adiponectin and fetuin-A are independently associated with incident
type 2 diabetes in humans, and the major mechanisms involved.
Methods: Relationships with incident diabetes were tested in two cohort studies: within the European Prospective
Investigation into Cancer and Nutrition (EPIC)-Potsdam study (628 cases) and the Nurses’ Health Study (NHS; 470 cases).
Relationships with body fat compartments, insulin sensitivity and insulin secretion were studied in the Tu ¨bingen Lifestyle
Intervention Program (TULIP; N=358).
Results: Circulating adiponectin and fetuin-A, independently of several confounders and of each other, associated with risk
of diabetes in EPIC-Potsdam (RR for 1 SD: adiponectin: 0.45 [95% CI 0.37–0.54], fetuin-A: 1.18 [1.05–1.32]) and the NHS (0.51
[0.42–0.62], 1.35 [1.16–1.58]). Obesity measures considerably attenuated the association of adiponectin, but not of fetuin-A.
Subjects with low adiponectin and concomitantly high fetuin-A had the highest risk. Whereas both proteins were
independently (both p,1.8610
27) associated with insulin sensitivity, circulating fetuin-A (r=20.37, p=0.0004), but not
adiponectin, associated with insulin secretion in subjects with impaired glucose tolerance.
Conclusions: We provide novel information that adiponectin and fetuin-A independently of each other associate with the
diabetes risk. Furthermore, we suggest that they are involved in the development of type 2 diabetes via different
mechanisms, possibly by mediating effects of their source tissues, expanded adipose tissue and nonalcoholic fatty liver.
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Among several pathways involved in the pathogenesis of the
epidemically spreading disease type 2 diabetes, an altered
secretory pattern of the expanded and inflamed adipose tissue is
thought to be important for the regulation of insulin sensitivity and
subclinical inflammation in various tissues [1]. In this respect
adiponectin has gained much attention in the past years because
the circulating levels of this adipokine are not only markers of type
2 diabetes risk, but because adiponectin is strongly involved in its
progression [2]. In analogy to dysregulated adipose tissue [2–4],
there is increasing evidence that nonalcoholic fatty liver disease
(NAFLD), which predictive of metabolic diseases [5–10], is also
associated with an altered secretory pattern of proteins, which can
be referred to as hepatokines, and which are both markers of the
disease, and are involved in its pathophysiology [11]. Among them
fetuin-A gained much attention during the recent years because of
its association with type 2 diabetes and cardiovascular disease risk
[12-17]. and its important role in the pathogenesis of insulin
resistance and subclinical inflammation [18–23].
In the present study we now asked two questions: first, to what
extent are circulating levels of these proteins related to incident
type 2 diabetes independently of each other? Second, because the
circulating levels of these two proteins strongly reflect the
dysregulation of their source tissues, adipose tissue and liver, can
they be used to estimate the contribution of expanded and
inflamed adipose tissue and NAFLD to the pathogenesis of insulin
resistance and impaired beta cell function?
For this we investigated associations of circulating adiponectin
and fetuin-A with incident type 2 diabetes by applying a head to
head comparison of these proteins in two large cohort studies, the
European Prospective Investigation into Cancer and Nutrition
(EPIC)-Potsdam study and the Nurses’ Health Study (NHS). In
addition, we studied the independent relationships of the
circulating levels of these proteins with precisely measured body
fat mass and distribution, liver fat content, insulin sensitivity and
insulin secretion in subjects of the Tu ¨bingen Lifestyle Intervention
Program (TULIP).
Subjects and Methods
EPIC-Potsdam study
The EPIC-Potsdam Study is part of the multi-centre prospective
cohort study EPIC [24]. In Potsdam, Germany, 27,548 subjects
(16,644 women and 10,904 men) were recruited from the general
population between 1994 and 1998. The age range was 35–65
years in women and 40–65 years in men. The baseline
examination included anthropometric measurements, a personal
interview including questions about prevalent diseases, and a
questionnaire about socio-demographic and lifestyle characteristics
[13]. Follow-up questionnaires were sent out every 2 to 3 years to
identify incident cases of type 2 diabetes. All incident cases of
diabetes identified were verified by treating physicians. Biochem-
ical measurements were carried out in a case-cohort design nested
within the cohort, details of which have been published previously
[13]. Briefly, we randomly selected a subcohort of 2,500
individuals of whom 2,095 were non-diabetic at baseline (based
on self-report and blood glucose determinations) and had
anamnestic, anthropometrical and metabolic data for analysis.
Of the 849 incident diabetes cases identified in the full cohort
during an average follow-up of 7 years 628 remained for analyses
after similar exclusions. Informed consent was obtained from all
participants, and approval was given by the Ethical Committee of
the State of Brandenburg, Germany.
NHS
A total of 121,700 registered nurses living in one of 11 populous
U.S. states composed the NHS when they responded to a
questionnaire inquiring about their medical history and lifestyle
characteristics in 1976 [15]. In 2000–2001, 18,717 NHS
participants aged 53–79 years provided blood samples. Among
these participants, a prospective, nested, case-control study was
conducted to examine plasma biomarkers in relation to type 2
diabetes risk. After excluding women with self-reported prevalent
diabetes, cardiovascular disease, or cancer at baseline, 470 cases of
type 2 diabetes cases from the date of blood draw through June
2006 were prospectively identified and confirmed. Risk-set
sampling was used to randomly select one control for each case
from the rest of population who remained free of diabetes when
the case was diagnosed; the probability of being selected as a
control is proportional to the length of follow-up. Cases and
controls were further matched for age at blood draw (61 year),
date of blood draw (63 months), fasting status (fast for 8 h or not),
and race (white or other races) [15]. The study protocol was
approved by the institutional review board of the Brigham and
Women’s Hospital and the Human Subjects Committee Review
Board of Harvard School of Public Health.
TULIP
A total of 358 Caucasians, who participated in the Tu ¨bingen
Lifestyle Intervention Program (TULIP) [24], were included in the
present analyses because they fulfilled at least one of the following
criteria: a family history of type 2 diabetes, a BMI.27 kg/m
2,
previous diagnosis of impaired glucose tolerance or gestational
diabetes. Informed written consent from subjects participating in
the Tu ¨bingen studies was obtained and the Ethical Committee of
the University of Tu ¨bingen, Germany had approved the protocols.
Anthropometrics and metabolic parameters were measured as
previously described [13,25,26]. Glucose tolerance was deter-
mined according to the 1997 World Health Organization
diagnostic criteria [27]. Insulin sensitivity from the OGTT was
estimated as proposed by Matsuda and DeFronzo [28]. In a
subgroup (N=244) insulin sensitivity was also measured during a
euglycemic, hyperinsulinemic clamp [26]. The insulinogenic
index, a precise estimate of glucose-induced insulin secretion,
was assessed from the OGTT as follows: (insulin at 30 min-insulin
at 0 min)/(glucose at 30 min-glucose at 0 min).
Measurement of adiponectin and fetuin-A
In the EPIC-Potsdam study and in the TULIP study
adiponectin levels were determined with enzyme-linked immuno-
sorbent assays (ELISA, Linco Research, Inc., St Charles, MO).
Fetuin-A levels were measured using an immunoturbidimetric
method (BioVendor Laboratory Medicine, Modreci, Czech
Republic). In the NHS, both, adiponectin and fetuin-A levels
were measured by enzyme immunoassays from R&D Systems
(Minneapolis, MN).
Statistical analyses
In the EPIC Study and the NHS adiponectin and fetuin-A levels
were categorized into quintiles based on subcohort or control
participants. Hazard ratios as a measure of relative risk (RR) were
computed using a weighted Cox proportional hazards model in
EPIC-Potsdam, modified for the case-cohort design according to
the Prentice method. Age was the underlying time variable in the
counting processes, with entry defined as the subjects’ age at the
time of recruitment and exit defined as age at the diagnosis of
diabetes, or censoring. In NHS, odds ratios were calculated using
Adiponectin, Fetuin-A and Risk of Type 2 Diabetes
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tions [15].
We computed RRs/ORs for each quintile of adiponectin and
fetuin-A compared with the lowest quintile. The significance of
linear trends across quintiles of adiponectin and fetuin-A was
tested by assigning each participant the median value for the
quintile and modeling this value as a continuous variable. Because
this analysis indicated no department from linearity, we also
considered adiponectin and fetuin-A as continuous variable
estimating the RR/OR associated with an increment of 1 SD.
We used information on covariates obtained from the baseline
examination in multivariate analyses, namely sex, education,
physical activity, smoking, and alcohol intake. Analyses in NHS
were further adjusted for other matching factors beyond age (race,
fasting status, time of blood drawing), as well as for body mass
index (BMI) and waist circumference.
In the TULIP study, data are given as means6SE. Data that
were not normally distributed (e.g. liver fat, insulin sensitivity,
body fat distribution; Shapiro-Wilk W test) were logarithmically
transformed. A p-value#0.05 was considered statistically signifi-
cant.
Results
Association of circulating adiponectin and fetuin-A with
diabetes incidence in the EPIC-Potsdam Study and the
NHS
The adjusted RRs/ORs of type 2 diabetes for quintiles of
fetuin-A and adiponectin in the EPIC-Potsdam study and the
NHS are shown in table 1. Higher levels of fetuin-A were
associated with an increased risk of diabetes, independent of
adiponectin (RR/OR comparing extreme quintiles: EPIC-Pots-
dam: 1.23 [95% CI: 0.88–1.72], p for trend ,0.01; NHS: 2.05
[1.24–3.37]). Contrary, higher adiponectin levels were associated
with lower risk of diabetes in both cohorts (RR/OR comparing
extreme quintiles: EPIC-Potsdam: 0.20 [0.13–0.30]; NHS: 0.18
[0.10–0.32]). Considering fetuin-A and adiponectin as continuous
variables (per 1 SD increment), revealed a similar picture with
consistent inverse associations for adiponectin and positive
Table 1. Risk of type 2 diabetes by quintiles of plasma adiponectin and fetuin-A.
Quintiles of biomarker P Trend
1 2345
EPIC-Potsdam*
Adiponectin
Median (mg/ml) 3.83 6.23 8.13 9.96 13.4
Cases 253 148 106 77 44
Relative Risk (95% CI) 1.00 0.49 0.37 0.34 0.20 ,0.0001
(0.36, 0.66) (0.27, 0.51) (0.24, 0.48) (0.13, 0.30)
Fetuin-A
Median (mg/ml) 178 221 249 280 323
Cases 102 100 124 137 165
Relative Risk (95% CI) 1.00 0.68 0.96 1.21 1.23 0.0085
(0.47, 0.99) (0.68, 1.37) (0.86, 1.70) (0.88, 1.72)
Nurses’ Health Study
#
Adiponectin
Median (mg/ml) 4.59 6.53 8.62 11.2 16.0
Case/control 245/94 83/94 78/94 39/94 25/94
Odds Ratio (95% CI) 1.00 0.34 0.40 0.23 0.18
(0.23, 0.52) (0.26, 0.61) (0.14, 0.38) (0.10, 0.32) ,0.0001
Fetuin-A
Median (mg/ml) 347 421 474 535 626
Case/control 59/94 79/94 80/94 124/94 128/94
Odds Ratio (95% CI) 1.00 1.16 1.49 2.06 2.05 0.0008
(0.69, 1.93) (0.89, 2.49) (1.26, 3.36) (1.24, 3.37)
*Adiponectin and fetuin-A included simultaneously in the model; Adjusted for age, sex, BMI, waist circumference, education (in or no training, vocational training,
technical school, or technical college or university degree), occupational activity (light, moderate, heavy), sport activity (0, 0.1–4.0, .4.0 h/week), cycling (0, 0.1–2.4, 2.5–
4.9, $5.0 h/week), smoking (never, past, current ,20 cigarettes/d, current .=20 cigarettes/d), and alcohol intake (0, 0.1–5.0, 5.1–10.0, 10.1–20.0, 20.1–40.0, .40.0 g/d).
#Adiponectin and fetuin-A included simultaneously in the model. In addition, multivariate model was adjusted for matching factors, including age at blood draw (yrs),
race (white or not), fasting status (yes, no), and time of blood drawing, as well as body mass index (kg/m2), waist circumference (cm), smoking status (current smoker,
past smoker, non-smoker), physical activity (in tertiles), alcohol use (abstainer, ,5.0 g/day, 5.0–14.9 g/day, $15.0 g/day), and education (registered nurse, bachelor,
master and higher).
doi:10.1371/journal.pone.0092238.t001
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circumference attenuated the associations of adiponectin (by 29%
in EPIC-Potsdam and 28% in NHS). However, the association of
fetuin-A with diabetes risk was largely unaffected by adjustment
for BMI and waist circumference (Table 2).
We then examined the joint effect of circulating adiponectin
and fetuin-A by cross classifying participants by both variables
using sex-specific medians as cut-offs. The RR/OR for the
combination of a high fetuin-A- and a low adiponectin level
compared with the opposite extreme was 3.54 (95% CI: 2.54–4.95)
in EPIC-Potsdam and 4.61 (2.87–7.38) in NHS (Figure 1, A/B).
Tests for interaction were non-significant in both cohorts.
Cross-sectional relationships in the TULIP
The 358 TULIP subjects had a mean age of 46 years and a
mean BMI of 30 kgNm
22. To investigate relationships of
circulating adiponectin and fetuin-A levels with metabolic traits
we performed analyses in the total population and in subjects with
normal glucose tolerance (NGT) and impaired glucose tolerance
(IGT) separately (Table 1 in File S1).
Relationships of circulating adiponectin and fetuin-A with
body fat content and distribution and with insulin
sensitivity. In the total population circulating adiponectin,
adjusted for age and gender, correlated negatively with BMI (r=
20.19, p=0.0004) and with waist circumference (r=20.26,
p,0.0001). Negative correlations were also found with total body
fat mass (r=20.15, p=0.008) and, more strongly, with visceral fat
mass (r=20.40, p,0.0001) and with liver fat content (r=20.28,
p,0.0001). Circulating fetuin-A correlated only very weakly with
BMI (r=0.11, p=0.04) and not statistically significant with waist
circumference (r=0.10, p=0.06), total body fat mass- (r=0.07,
p=0.25), and visceral fat (r=0.07, p=0.20) mass. However, a
positive correlation with liver fat content was found (r=0.12,
p=0.04). In multivariate models including age and sex, both
circulating adiponectin and fetuin-A were strongly and indepen-
dently associated with insulin sensitivity estimated from the
OGTT and measured during the clamp (Table 3, models 1).
Inclusion of BMI and waist circumference in the models
attenuated the associations of circulating adiponectin (change of
the b; OGTT: 237%, clamp: 231%) on insulin sensitivity, but
less so of circulating fetuin-A (OGTT: 217%, clamp: 218%)
(Table 3, models 2). Similar relationships were found when these
analyses were performed in subjects with and without NAFLD
(OGTT: total N=291, NAFLD=93; clamp: total N=203,
NAFLD=63). Here inclusion of BMI and waist circumference
in the models attenuated the associations of circulating adiponec-
tin with insulin sensitivity, particularly in subjects without NAFLD
(change of the b; OGTT: 232%, clamp: 234%), while this
association was only slightly attenuated or even became stronger in
the smaller group of subjects with NAFLD (OGTT: 27%, clamp:
+18%). The respective relationships of fetuin-A with insulin
sensitivity were less strongly affected, both, in subjects without
(OGTT: 212%, clamp: 213%) and with (OGTT: 26%, clamp:
24%) NAFLD. After additional inclusion of liver fat content in the
models 2, the associations of adiponectin and fetuin-A with insulin
sensitivity were further attenuated and adiponectin, fetuin-A and
liver fat content independently determined insulin sensitivity
(Table 3, models 3). When we then divided non-obese subjects
(N=207) by the median insulin sensitivity estimated by the
OGTT (13.78 arb.u.) we found circulating fetuin-A (OR for 1 SD:
Table 2. Relative Risk of type 2 diabetes for plasma adiponectin and fetuin-A and attenuation of the risk by BMI and waist
circumference.
Adiponectin Fetuin-A
RR/OR 1 SD % change RR/OR 1 SD % change
EPIC-Potsdam
Model 1 * 0.35 Ref 1.21 Ref
(0.29, 0.41) (1.09, 1.34)
Model 1 + BMI 0.43 +22.9 1.19 21.7
(0.36, 0.52) (1.06, 1.33)
Model 1 + BMI + waist circumference 0.45 +28.6 1.18 22.5
(0.37, 0.54) (1.05, 1.32)
Nurses’ Health Study
Model 1
# 0.40 Ref 1.32 Ref
(0.33–0.48) (1.14–1.53)
Model 1 + BMI 0.47 +17.5 1.38 +4.5
(0.39–0.57) (1.18–1.61)
Model 1 + BMI + waist circumference 0.51 +27.5 1.35 +2.3
(0.42–0.62) (1.16–1.58)
*Relative Risk adjusted for age, sex, education (in or no training, vocational training, technical school, or technical college or university degree), occupational activity
(light, moderate, heavy), sport activity (0, 0.1–4.0, .4.0 h/week), cycling (0, 0.1–2.4, 2.5–4.9, $5.0 h/week), smoking (never, past, current ,20 cigarettes/d, current $20
cigarettes/d), and alcohol intake (0, 0.1–5.0, 5.1–10.0, 10.1–20.0, 20.1–40.0, .40.0 g/d).
# Odds Ratio adjusted for matching factors, including age at blood draw (yrs), race (white or not), fasting status (yes, no), and time of blood drawing, as well as smoking
status (current smoker, past smoker, non-smoker), physical activity (in tertiles), alcohol use (abstainer, ,5.0 g/day, 5.0–14.9 g/day, $15.0 g/day), and education
(registered nurse, bachelor, master and higher).
doi:10.1371/journal.pone.0092238.t002
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[0.77–1.01]) or hs-CRP levels (1.04 [0.98–1.11]) to predict the
insulin resistant state, independently of age, sex, BMI and waist
circumference. Similar relationships were found when NGT and
IGT were analyzed separately (data not shown).
When we divided participants by the medians of circulating
adiponectin and fetuin-A levels, individuals with low adiponectin
and high fetuin-A levels had the lowest insulin sensitivity
compared to the other groups (Figure 1, C/D).
Relationships of circulating adiponectin and fetuin-A with
insulin secretion. We next investigated whether circulating
fetuin-A may be associated with glucose-induced insulin secretion
in humans. In the total population circulating fetuin-A did not
correlate with the insulinogenic index (r,0.01 p=0.99) when
adjusted for age, gender and insulin sensitivity measured during
the OGTT. However, this association depended on glucose
tolerance status: while fetuin-A did not correlate with the
insulinogenic index in subjects with NGT, a strong negative
correlation between fetuin-A levels and the insulinogenic index
was found in subjects with IGT (r=20.37, p=0.0004) (p for
interaction=0.024) (Figure 2, A/B). No significant relationships
were found for circulating adiponectin with the adjusted insulino-
genic index (all p.0.055).
Discussion
During the last decade much effort has been made to identify
importantpathwaysinvolvedinthenaturalhistoryoftype2diabetes.
Thereby,severalcandidatesweredescribed,predominantlybasedon
animal and on in-vitro studies [29–31]. However, often it was not
possible to prove these pathways to be of high relevance for human
metabolism. In human studies, on the other hand, several blood,
genetic or phenotypic markers were found to predict incident type 2
diabetes [1–4]. Nevertheless, no precise mechanisms of action for
several of these parameters are known and/or their predictive effect
on the development of type 2 diabetes was either small or absent,
which sofar limitstheir potential inthe prevention andthe treatment
of the disease.
Because these limitations largely do not apply to the adipokine
adiponectin and the hepatokine fetuin-A, we here investigated to
what extent circulating adiponectin and fetuin-A determine
incident type 2 diabetes, independently of each other. Towards
Figure 1. Relative risk (in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study; Panel A) and
Odds Ratio (in the Nurses’ Health Study; Panel B) of type 2 diabetes for joint classifications of plasma adiponectin and fetuin-A.
Groups with high/low adiponectin and fetuin-A levels were defined based on sex-specific medians. RRs were adjusted for age, sex, education,
occupational activity, sport activity, cycling, smoking, alcohol intake, BMI, and waist circumference in EPIC-Potsdam and ORs for matching factors,
including age at blood draw, race, fasting status, and time of blood drawing, as well as smoking status, physical activity, alcohol use, and education in
the Nurses’ Health Study. Relationship of circulating adiponetin and fetuin-A with insulin sensitivity estimated from the oral glucose tolerance test
(OGTT; N=358, C) and measured during the euglycemic, hyperinsulinemic clamp (N=244, D). Subjects were divided by the medians of circulating
adiponectin and fetuin-A in groups with high and low levels. P for trend after adjustment for age and sex.
doi:10.1371/journal.pone.0092238.g001
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investigated the associations of circulating adiponectin and
fetuin-A with incident type 2 diabetes by applying a head to head
comparison of these proteins in two large cohort studies, the
EPIC-Potsdam study and the NHS. In both studies we found that
circulating adiponectin and fetuin-A were associated with risk of
incident diabetes, independently of several confounders, and of
each other. The consistency of the association suggests that it
might be generalizable to healthy populations, at least to those
with Caucasian origin. Because the strength of association of
adiponectinemia, but not of circulating fetuin-A, was considerably
attenuated after accounting for estimates of overall and visceral
obesity, our data support that the adiponectin levels confer at least
in part the effect of obesity on the type 2 diabetes risk. In contrast,
the association of fetuin-A with diabetes risk does not appear to
considerably depend on body fatness. Rather the available
information from our and other studies suggest that the increase
in circulating fetuin-A and the resulting decrease in insulin
sensitivity may be a result of inflamed NAFLD [11,32–35].
We then focused on the relationship of both circulating proteins
with anthropometrics and metabolic traits in precisely phenotype
subjects of TULIP. We confirmed the strong correlations of
adiponecinemia with measures of body fat mass and distribution in
these subjects as well as the absence of such relationships for
fetuin-A levels. Based on the known properties of adiponectin and
fetuin-A to regulate insulin sensitivity, we confirmed that the
circulating levels of these proteins were independently of each
other associated with insulin sensitivity, estimated from the OGTT
or measured by a euglycemic, hyperinsulinemic clamp. In
agreement with the findings from the EPIC-Potsdam study and
the NHS, the relationship of circulating adiponectin, but not of
fetuin-A, was considerably attenuated after accounting for
measurements of body fat content and distribution. Consequently
we asked the question whether circulating fetuin-A may be a better
predictor of insulin sensitivity than circulating adiponectin in
subjects who are non-obese and could confirm this hypothesis in
our study.
Having found strong independent associations of circulating
adiponectin and fetuin-A, the two proteins that regulate insulin
sensitivity, on the diabetes risk, we then asked whether they may
differentially impact on insulin secretion, and thereby have distinct
effects in the pathogenesis of type 2 diabetes. For adiponectin we
have previously shown that this protein does not influence glucose-
induced insulin secretion in humans [36]. In the present study we
could show that fetuin-A levels are not associated with insulin
secretion in our subjects. Based on the knowledge that subjects
with IGT have an impaired beta cell function [37,38], we then
tested the hypothesis that fetuin-A is particularly relevant
specifically in this population that is at very high risk for the
disease. Indeed, when we separated the individuals in those with
NGT and IGT, a strong negative relationship of fetuin-A with
insulin secretion was found in subjects with IGT.
What is the relevance of our data for clinicians and researchers?
Because the relative risk of incident diabetes was much higher for
the combination of a high fetuin-A- and a low adiponectin level,
than for the single circulating level of each protein, it may be
Table 3. Determinants of insulin sensitivity in multivariate regression models in TULIP.
Insulin sensitivityOGTT Insulin sensitivityClamp
Covariates Estimate±SE F-value p Estimate±SE F-value p
Models 1
Female sex 0.0460.03 1.3 0.25 0.00360.04 0.0 0.93
Age 20.2960.11 6.8 0.01 20.3160.13 6.0 0.015
Adiponectin levels 0.3860.07 30.4 ,0.0001 0.5260.08 43.5 ,0.0001
Fetuin-A levels 20.8560.16 28.4 ,0.0001 20.7260.18 16.1 ,0.0001
Models 2
Female sex 20.0160.04 0.24 0.63 20.0360.04 0.5 0.48
Age 20.1760.10 2.6 0.11 20.1760.11 2.3 0.13
Adiponectin levels 0.2460.06 14.2 0.0002 0.3660.07 25.3 ,0.0001
Fetuin-A levels 20.7060.14 23.8 ,0.0001 20.5960.16 14.4 0.0002
BMI 220.5460.31 3.0 0.08 21.0560.33 10.1 0.002
Waist circumference 21.1660.43 7.4 0.007 20.6860.45 2.3 0.13
Models 3 *
Female sex 20.00460.04 0.01 0.91 20.0360.04 0.6 0.44
Age 20.0960.10 0.7 0.39 20.00760.11 0.004 0.95
Adiponectin levels 0.1760.07 6.5 0.01 0.2760.07 14.2 0.0002
Fetuin-A levels 20.6960.15 22.9 ,0.0001 20.4860.16 9.2 0.003
BMI 20.9160.34 7.2 0.008 20.9160.36 6.4 0.01
Waist circumference 0.1360.43 0.07 0.79 20.0660.50 0.02 0.90
Liver fat content 20.2060.03 52.0 ,0.0001 20.2060.03 48.2 ,0.0001
*N=291 for insulin sensitivityOGTT and N=203 for insulin sensitivityClamp.
doi:10.1371/journal.pone.0092238.t003
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the prediction of the risk of future type 2 diabetes. Whether fetuin-
A and adiponectin improve prediction of diabetes risk beyond
waist circumference and other classical risk factors remains,
however, uncertain. Furthermore, fetuin-A may become an
important determinant of insulin resistant states, particularly in
non-obese subjects where adiponectin and hs-CRP levels lost their
strong predictive power in our study.
For researchers we provide novel information that adiponectin
and fetuin-A are independently involved in the pathogenesis of
type 2 diabetes. Both proteins impact on the development of the
disease predominantly be the regulation of subclinical inflamma-
tion. Furthermore, we have support for the hypothesis that they
mediate the effects of their source tissues, expanded adipose tissue
and inflamed nonalcoholic fatty liver on glucose metabolism and
cardiovascular disease. In addition, we provide explorative
information about a putatively newly identified cross-talk of the
liver with the endocrine function of the pancreas. Whether there
are direct effects of fetuin-A on signalling cascades in beta cells or
whether fetuin-A induces a chronic pro-inflammatory process in
the human islets needs to be investigated in future studies.
Some possible limitations of our findings have to be considered.
The potential of residual confounding applies to our study as it
does to observational studies in general. We adjusted for a large
variety of known risk factors. Although fetuin-A and adiponectin
remained significantly associated with diabetes risk, we cannot rule
out that other unmeasured factors or that imprecision in the
measurement of covariates explain this observation. Also, we only
had a single blood drawing which might have introduced random
measurement errors in determining fetuin-A and adiponectin. The
lack of repeated measurements may have led to an underestimation
oftheobserved associations.Inconclusion,ourfindingssupport that
the adipokine adiponectin and the hepatokine fetuin-A are reliable
predictors ofincidenttype2 diabetesandinsulin resistance,and that
they are strongly and independently of each other involved in their
pathogenesis. Moreover, we could provide indirect support that
adiponectin mediates, at least in part, the impact of dysregulated
and expanded visceral fat on metabolism, whereas increased fetuin-
A levels are largely a result of NAFLD. Finally, we provided novel
exploratory information that fetuin-A may play a role in the
pathogenesis of type 2 diabetes by affecting insulin secretion.
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